Helius Medical Technologies (OTCMKTS:HSDT) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Helius Medical Technologies (OTCMKTS:HSDT) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Helius Medical Technologies Inc. is a specialty medical device company. It is focused on the development and regulatory approval of its non-invasive neurostimulation device called PoNS. The Company is nearing clinical trials for balance disorders in TBI patients and for the treatment of MS. Helius Medical Technologies, Inc. is based in Newtown, Pennsylvania. “

OTCMKTS:HSDT traded up $0.12 during mid-day trading on Wednesday, hitting $1.16. The stock had a trading volume of 954,514 shares, compared to its average volume of 395,823. The stock has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $1.49. Helius Medical Technologies has a twelve month low of $0.28 and a twelve month high of $8.62.

Helius Medical Technologies (OTCMKTS:HSDT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.30 million.

A number of large investors have recently bought and sold shares of HSDT. Bank of Montreal Can lifted its holdings in Helius Medical Technologies by 6,777.4% during the 2nd quarter. Bank of Montreal Can now owns 20,701 shares of the company’s stock worth $45,000 after buying an additional 20,400 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Helius Medical Technologies during the 2nd quarter worth about $35,000. Paloma Partners Management Co purchased a new stake in Helius Medical Technologies during the second quarter worth approximately $177,000. Morgan Stanley lifted its stake in Helius Medical Technologies by 302.7% during the second quarter. Morgan Stanley now owns 14,072 shares of the company’s stock worth $31,000 after purchasing an additional 10,578 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Helius Medical Technologies by 627.9% during the third quarter. Millennium Management LLC now owns 207,895 shares of the company’s stock worth $343,000 after purchasing an additional 179,336 shares during the last quarter.

About Helius Medical Technologies

Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.

Read More: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on Helius Medical Technologies (HSDT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.